Sugi Predict

Sugi Predict / Compounds / SCHEMBL229798

SCHEMBL229798

SCHEMBL229798

O=[N+]([O-])c1ccc(Br)cc1O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR35 Q9HC97 4/20 0.62
▸ MAPT P10636 3/20 0.47
▸ HPGD P15428 3/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ CYP3A4 P08684 2/20 0.47
▸ HSD17B10 Q99714 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ RECQL P46063 1/20 0.47
▸ BLM P54132 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ TP53 P04637 2/20 0.47
▸ TSHR P16473 2/20 0.47
▸ MAPK1 P28482 2/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ SIRT6 Q8N6T7 1/20 0.46
▸ THRB P10828 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29751827 1.00 GPR35 (0.62) GPR35MAPTHPGDALDH1A1CYP3A4
SCHEMBL28259735 0.98 GPR35 (0.60) GPR35MAPTHPGDALDH1A1CYP3A4
Bicarbonate SCHEMBL28099419 0.93 GPR35 (0.55) GPR35MAPTHPGDALDH1A1CYP3A4
SCHEMBL31572456 0.83 HPGD (0.62) GPR35MAPTHPGDALDH1A1CYP3A4
SCHEMBL7524 0.83 HPGD (0.62) GPR35MAPTHPGDALDH1A1CYP3A4
Hydrogen Sulfide SCHEMBL28313840 0.82 HPGD (0.60) GPR35MAPTHPGDALDH1A1CYP3A4
SCHEMBL1561802 0.80 TSHR (0.56) GPR35MAPTHPGDALDH1A1CYP3A4
Nitrophenolate SCHEMBL28780638 0.80 GPR35 (0.53) GPR35MAPTHPGDALDH1A1HSD17B10
SCHEMBL27895839 0.80 CTSB (0.61) GPR35MAPTHPGDALDH1A1CYP3A4
SCHEMBL29490141 0.78 GPR35 (0.67) GPR35MAPTHPGDALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 402 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118702085-A Method for regulating specific surface area of carbon material 三明学院 2024-09-27 — — CN claimed
CN-105968103-B The synthetic method of anti-tumor drug Afatinib 山东罗欣药业集团恒欣药业有限公司 2018-11-27 — — CN claimed
CN-105968103-A Synthesis method of anti-tumor medicine afatinib 山东罗欣药业集团恒欣药业有限公司 2016-09-28 — — CN claimed
US-7365231-B2 Compound with antitumor activity and preparation method therefor NATIONAL TAIWAN UNIVERSITY OF SCIENCE & TECHNOLOGY (TW) 2008-04-29 — — US claimed
US-20060241187-A1 Compound with antitumor activity and preparation method therefor NATIONAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (TW) 2006-10-26 — — US claimed
CN-1207269-C 1,3,5-tri(3-hydroxy-4-aminophenoxy)benzene and its hydrochlorides and preparation thereof UNIV SHANGHAI JIAOTONG (CN) 2005-06-22 — — CN claimed
CN-1203048-C 3,5-bi(3-hydroxy-4-aminophenoxy)benzoic acid and its hydrochlorides and preparation thereof UNIV SHANGHAI COMMUNICATION (CN) 2005-05-25 — — CN claimed
CN-1472192-A 3,5-bi(3-hydroxy-4-aminophenoxy)benzoic acid and its hydrochlorides and preparation thereof 上海交通大学 2004-02-04 — — CN claimed
CN-1472191-A 1,3,5-tri(3-hydroxy-4-aminophenoxy)benzene and its hydrochlorides and preparation thereof 上海交通大学 2004-02-04 — — CN claimed
EP-4741018-A2 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2026-05-13 — — EP disclosed
US-20260102404-A1 THYROID STIMULATING HORMONE RECEPTOR (TSHR) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2026-04-16 — — US disclosed
US-12583836-B2 Sulphonamide compounds Anaxis Pharma Pty Ltd (AU) 2026-03-24 — — US disclosed
EP-3573972-B1 RORGAMMA MODULATORS AND USES THEREOF GENFIT (FR) 2026-01-14 — — EP disclosed
EP-4168401-B1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2026-01-07 — — EP disclosed
EP-0841321-A1 Aromatic ethers of polyalkylphenoxyalkanols and fuel compositions containing the same CHEVRON CHEMICAL COMPANY (US) 1998-05-13 — — EP disclosed
US-5709720-A AS ANTIDEPOSIT AGENTS FOR USE IN ENGINES CHEVRON CHEMICAL COMPANY (US) 1998-01-20 — — US disclosed
EP-0669927-A1 SEQUENCE-SPECIFIC BINDING POLYMERS FOR DUPLEX NUCLEIC ACIDS ANTIVIRALS INC. (US) 1995-09-06 — — EP disclosed
US-5405938-A Hydrogen bonding an N-heterocyclic-substituted ribose-based polymer to a double-stranded DNA to block genetic activity, to diagnose for pathogens and to aid in genetic engineering ANTI-GENE DEVELOPMENT GROUP (US) 1995-04-11 — — US disclosed
WO-1994012517-A1 SEQUENCE-SPECIFIC BINDING POLYMERS FOR DUPLEX NUCLEIC ACIDS ANTIVIRALS INC. (US) 1994-06-09 — — WO disclosed
US-3984405-A PYRIDO(3,2-B)(1,4)OXAZIN-3(4H)-ONES E. R. SQUIBB & SONS, INC. (US) 1976-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260102404-A1 THYROID STIMULATING HORMONE RECEPTOR (TSHR) ANTAGONISTS AND USES THEREOF TSHR, TRHR, THRB GPR35 606/4885MAPT 4875/4885HPGD 3897/4885
US-12583836-B2 Sulphonamide compounds MLKL, RIPK3, CASP1 GPR35 4040/4885MAPT 1287/4885HPGD 3144/4885
US-20060241187-A1 Compound with antitumor activity and preparation method therefor WEE1, WEE2, CYP51A1 GPR35 2929/4885MAPT 4457/4885HPGD 236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.